BrainPatch

BrainPatch operates at the intersection of neuroscience, wellness, consumer health, and neurotechnology, with a stated focus on non-invasive brain stimulation. Its e-Meditation Neuroheadset is positioned around rapid relaxation and stress support, while the BrainPatch VR Stimulator extends the company’s stated product scope to vestibular stimulation for motion sickness and virtual experiences. The competitive landscape is therefore best understood by category: consumer wellness wearables, neurostimulation devices, and immersive-technology accessories. BrainPatch’s stated differentiators are its non-invasive stimulation approach, AI-enabled personalization, and patented technology; its product information also describes individualized stimulation as important. Four granted patents and four registered trademarks indicate some formal intellectual-property activity, but do not by themselves demonstrate a defensible advantage. Its 2025 Selfridges debut and US availability through Caputron provide evidence of retail and specialist-channel access, not market share.

BrainPatch was founded in 2018 and has built its trajectory around non-invasive stimulation, with product concepts spanning a relaxation-focused e-Meditation headset and a VR-compatible stimulator. Its structured funding history lists two pre-seed rounds—$550,000 on Jun 25, 2020 and $500,000 on Jul 7, 2021—alongside an €71,429 grant, recorded as $81,868, on Jan 1, 2019. Those entries total $1,131,868, the reported structured funding total. A notable commercial inflection came in August 2025: the e-Meditation Neuroheadset launched at Selfridges in London and became available in the US through Caputron. That same month, Jamie Urquhart joined as an adviser, while a published article described a $2 million fundraising target. The company has also indicated that it is scaling manufacturing and operations to fulfill growing orders, but no headcount trend, order volume, or completed financing against that target is confirmed. The evidence suggests a shift toward commercialization, while the scale and pace of growth remain difficult to quantify.